HD-OPM Archive
Topics › Heart rhythm & heart failure

Dapagliflozin linked to lower heart failure risk in carriers of cardiomyopathy variants

Louis Nervegna · Jun 13, 2026 · ♥ 5 reactions · 1 comments · original Facebook post
Heart rhythm & heart failureInsulin resistance & diabetes
AI summary & key facts

Louis shares a Nature Medicine study of over 12,000 adults with type 2 diabetes in which dapagliflozin was associated with significantly lower heart failure risk in those carrying inherited cardiomyopathy-related variants. Fox News describes an 8-fold reduction in heart failure hospitalization, and suggests genetic screening could eventually guide early treatment.

Use of the SGLT2 inhibitor dapagliflozin is linked with significantly lower risk of heart failure in patients with genetic predisposition for cardiomyopathy.

#sglt2HD #dapagliflozinHD #cardiomyopathyHD #hcmHD

Research cited

CARDIAC BOOST: A common diabetes drug slashed heart failure risk by 8x in patients carrying a genetic variant linked to cardiomyopathy, according to a new study in Nature Medicine.

Researchers analyzed over 12,000 adults with type 2 diabetes and found that dapagliflozin dramatically reduced hospitalization for heart failure in those with inherited gene variants.

The findings could eventually lead cardiologists to use genetic screening to identify high-risk patients and begin treatment before symptoms ever appear.

No photo description available.
← newer: Low-insulinemic and Planetary Health diets tied to less weigolder: Semaglutide-driven visceral fat loss slowed epigenetic aging →